Intellia Therapeutics Reports Successful Phase 3 Trial for Crispr-Based Gene Therapy

Key Facts

Intellia Therapeutics has announced that its Phase 3 HAELO trial of lonvo-z met its primary and key secondary endpoints with a favorable safety profile. The trial results demonstrated that 62% of patients remained free of HAE attacks, significantly outperforming the 11% rate observed in the placebo group. Following the release of this positive clinical data, NTLA shares surged in pre-market trading. The company has officially initiated a rolling Biologics License Application (BLA) submission with the U.S. FDA. Intellia anticipates a commercial launch in the United States in the first half of 2027, pending final regulatory approval. Investors are closely monitoring the company's progress as it moves toward commercializing this definitive gene-editing therapeutic solution.

Version History